Calithera Biosciences, Inc. (NASDAQ:CALA – Get Free Report) crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0004. Calithera Biosciences shares last traded at $0.0004, with a volume of 625 shares.
Calithera Biosciences Stock Performance
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company is focused on the discovery and development of small molecule inhibitors that target metabolic pathways critical to the growth and survival of cancer cells. By disrupting tumor metabolism, Calithera aims to create novel therapeutic options for patients with solid tumors and hematologic malignancies.
The company’s pipeline includes lead candidates such as telaglenastat (CB-839), a glutaminase inhibitor being evaluated in multiple Phase 2 trials across various tumor types, and CB-1158, an arginase inhibitor designed to reprogram the tumor microenvironment and enhance anti-tumor immunity.
Recommended Stories
- Five stocks we like better than Calithera Biosciences
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
